ARWR
ARROWHEAD PHARMACEUTICALS, INC. · Healthcare · Market cap $8.3B
Insiders sold $1.2M net in the last 90 days ·2 sellers, 0 buyers· latest Form 4 filed Aug 20, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$37.3M
reported sales (SEC code S)
Unique Insiders
10
in the rolling window
Latest filing
Aug 20, 2026
OLUKOTUN ADEOYE Y
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has 30 SEC Form 4 filings (88 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Aug 20, 2026.
Inside the rolling window, 10 insiders at ARROWHEAD PHARMACEUTICALS, INC. reported no open-market purchases and 21 open-market sales totaling $37.3M. The most active filer is Chief Executive Officer Anzalone Christopher Richard with 7 filings. Insiders have net sold $3.7M over the trailing 6 months. The most recent open-market filing is a sale of 2,000 shares by Director OLUKOTUN ADEOYE Y, dated Aug 18, 2026, worth $174K.
- Industry:Biotechnology
- CEO:Christopher R. Anzalone
- Employees:711
- HQ:Pasadena, CA, US
- IPO:1993-12-16
| Source | |||||||
|---|---|---|---|---|---|---|---|
OLUKOTUN ADEOYE YFirst in 8 months | Director | Sale | 2,000 | $174K | Aug 20 | -32.7% | SEC ↗ |
PERRY MICHAEL SFirst in 8 months | Director | Sale | 11,600 | $1.0M | Aug 20 | -32.7% | SEC ↗ |
| Director | Sale | 2,970 | $228K | May 14 | -26.2% | SEC ↗ | |
Apel Daniel JosephFirst filing | Chief Financial Officer | Sale | 13,095 | $934K | Apr 24 | -20.4% | SEC ↗ |
| Chief Medical Officer | Sale | 10,000 | $750K | Apr 24 | -20.4% | SEC ↗ | |
| Chief Medical Officer | Sale | 10,000 | $642K | Mar 9 | -3.0% | SEC ↗ | |
O'Brien PatrickFirst filing | COO | Sale | 49,493 | $3.1M | Jan 5 | -7.9% | SEC ↗ |
Hamilton James CFirst filing | Chief Medical Officer | Sale | 40,164 | $2.5M | Jan 5 | — | SEC ↗ |
| Chief Executive Officer | Sale | 13,187 | $872K | Jan 5 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 51,726 | $3.6M | Dec 30 | — | SEC ↗ | |
| Director | Sale | 7,530 | $527K | Dec 30 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 13,445 | $910K | Dec 23 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 12,586 | $861K | Dec 23 | — | SEC ↗ | |
Vakiener VictoriaFirst filing | Director | Sale | 10,040 | $679K | Dec 23 | — | SEC ↗ |
Waddill William D.First filing | Director | Sale | 8,367 | $566K | Dec 23 | — | SEC ↗ |
OLUKOTUN ADEOYE YFirst filing | Director | Sale | 10,000 | $677K | Dec 23 | — | SEC ↗ |
| Chief Executive Officer | Sale | 85,000 | $5.4M | Dec 19 | — | SEC ↗ | |
Anzalone Christopher RichardFirst filing | Chief Executive Officer | Sale | 130,000 | $9.0M | Dec 16 | — | SEC ↗ |
Anzalone Christopher RichardFirst filing | Chief Executive Officer | Sale | 54,298 | $3.4M | Dec 16 | — | SEC ↗ |
PERRY MICHAEL SFirst filing | Director | Sale | 16,250 | $992K | Dec 9 | — | SEC ↗ |
Ferrari MauroFirst filing | Director | Sale | 8,750 | $493K | Dec 1 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading ARWR 1 all-time
- DRep. Daniel GoldmanSale$1,001 - $15,0002023-01-31
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does ARWR have?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has 30 SEC Form 4 filings (88 transaction rows) in the rolling 365-day window, disclosed by 10 distinct insiders. Most recent filing: Aug 20, 2026.
When was the most recent SEC Form 4 filing for ARWR?
The most recent Form 4 filing for ARWR on Tracefour is dated Aug 20, 2026.
Who is the most active insider at ARWR?
The most active SEC Form 4 filer at ARWR in the rolling window is Chief Executive Officer Anzalone Christopher Richard, with 7 filings.
What is the net insider flow at ARWR over the last 6 months?
Over the trailing 180 days, insiders at ARWR have net sold $3.7M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ARWR in the current window?
Inside the rolling window, insiders at ARWR bought $0 and sold $37.3M based on SEC Form 4 filings.
Can I get alerts for ARWR insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at ARROWHEAD PHARMACEUTICALS, INC. (ARWR). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
ARROWHEAD PHARMACEUTICALS, INC. is in the Healthcare sector.